Alvotech SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 8731 https://www.oaktreeacquisitioncorp.com/oac-ii

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech SA

Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) - Feb 6th, 2023 9:00 am
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia - Jan 24th, 2023 9:00 am
Alvotech Completes $137 Million Private Share Placement - Jan 23rd, 2023 8:25 am
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate - Jan 13th, 2023 9:00 am
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® - Jan 11th, 2023 9:00 am
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Jan 6th, 2023 12:00 pm
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira® - Dec 22nd, 2022 9:00 am
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT - Dec 16th, 2022 11:45 am
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field - Dec 16th, 2022 11:45 am
Alvotech Completes $59.7 Million Private Placement - Dec 16th, 2022 9:00 am
Alvotech Shares Start Trading on Nasdaq Iceland Main Market - Dec 8th, 2022 8:30 am
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe - Dec 7th, 2022 9:00 am
Nasdaq Iceland Approves the Request for Trading of Alvotech’s Shares on the Main Market - Dec 2nd, 2022 3:41 pm
Alvotech Announces Changes to its Leadership Team - Dec 1st, 2022 10:00 pm
Alvotech Submits its Application for Admission of the Company’s Shares to Trading on Nasdaq Iceland Main Market - Nov 30th, 2022 7:47 pm
Alvotech Secures Financing Facilities of Approximately $136 Million - Nov 16th, 2022 12:27 pm
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update - Nov 16th, 2022 5:00 am
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira® - Nov 14th, 2022 7:00 am
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference - Nov 10th, 2022 9:00 am
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022 - Oct 27th, 2022 9:00 pm